Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2014

View Archived Issues

Takeda Pharmaceuticals charts milestones of second quarter of fiscal 2014

Daiichi Sankyo presents highlights of second quarter of fiscal 2014

Fujifilm to invest in PET radiopharmaceuticals

Xoma opens enrollment in phase III study of gevokizumab for pyoderma gangrenosum

AstraZeneca and Pharmacyclics collaborate on combination trials of ibrutinib in oncology

Cabozantinib extends progression-free survival in phase II trial in NSCLC

Astellas and Proteostasis Therapeutics form collaboration targeting the unfolded protein response

LEO Pharma licenses Japan Tobacco's JTE-052 for dermatology applications

Research uncovers novel gene mutations underlying familial hypertrophic cardiomyopathy

BioLineRx reports final results of phase I/II study for BL-7010

Alion and Medical Prognosis Institute to identify response biomarkers for ion channel inhibitor

Novel cystine derivatives inhibit stone formation in vivo

Aegerion Pharmaceuticals to acquire Myalept from AstraZeneca

New pan-RAF inhibitors effective in melanomas resistant to BRAF or BRAF/MEK inhibitors

Effectiveness of a bumped kinase inhibitor against toxoplasmosis

Novel ACC2 inhibitors disclosed by Boehringer Ingelheim

Incyte divulges novel FGFR-1, -2 and -3 inhibitors

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Astellas Pharma discloses new D1 receptor PAMs

Actelion researchers present novel antibacterial compounds

Investigators at CSIR report new anticancer rohitukine analogues

Beloranib as promising treatment of obesity and food-related behavior in Prader-Willi Syndrome

Spark Therapeutics' SPK-RPE65 receives FDA breakthrough therapy designation

Gilead files NDA for elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for HIV

FDA advisory committee recommends approval of Triferic

FDA issues complete response letter to AEterna Zentaris for Macrilen NDA

F-star spins off assets into F-star Beta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...